SECOND AMENDATORY AGREEMENT

This **SECOND AMENDATORY AGREEMENT** is made between the **CITY AND COUNTY OF DENVER**, a municipal corporation of the State of Colorado (the "City"), **DENVER DEPARTMENT OF PUBLIC HEALTH AND ENVIRONMENT** ("DDPHE"), and **DENVER HEALTH AND HOSPITAL AUTHORITY**, a body corporate and political subdivision of the State of Colorado, whose address is 777 Bannock Street, MC 1925, Denver, Colorado 80204 (the "Contractor"), jointly ("the Parties").

RECITALS:

- A. The Parties entered into an Agreement dated February 29, 2024, and an Amendatory Agreement dated February 21, 2025, (collectively, the "Agreement") to perform, and complete all of the services and produce all the deliverables set forth on **Exhibit A, the Scope of Work**, to the City's satisfaction.
 - **B.** The Parties wish to amend the Agreement to update the scope of work exhibit.

NOW THEREFORE, in consideration of the premises and the Parties' mutual covenants and obligations, the Parties agree as follows:

- 1. **Exhibit A** and **Exhibit A-1** are hereby deleted in its entirety and replaced with **Exhibit A-2 Scope of Work**, attached and incorporated by reference herein. All references in the original Agreement to **Exhibit A and Exhibit A-1** are changed to **Exhibit A-2**.
- 2. As herein amended, the Agreement is affirmed and ratified in each and every particular.
- 3. This Second Amendatory Agreement will not be effective or binding on the City until it has been fully executed by all required signatories of the City and County of Denver, and if required by Charter, approved by the City Council.

[THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.]

Contract Control Number: Contractor Name:	ENVHL-202579246-02 ENVHL-202370663-02 DENVER HEALTH AND HOSPITAL AUTHORITY			
IN WITNESS WHEREOF, the par Denver, Colorado as of:	rties have set their hands and affixed their seals at			
SEAL	CITY AND COUNTY OF DENVER:			
ATTEST:	By:			
APPROVED AS TO FORM:	REGISTERED AND COUNTERSIGNED:			
Attorney for the City and County of	Denver			
By:	By:			
	By:			

Contract Control Number: Contractor Name:

ENVHL-202579246-02 | ENVHL-202370663-02 DENVER HEALTH AND HOSPITAL AUTHORITY

Ву:	Signed by: Kimberly Fash 18GB4736343E4B8
Name:	Kimberly Fash (please print)
	(please print)
Title: _	Director, SPARO (please print)
	(please print)
ATTE	ST: [if required]
By:	
	(please print)
Title: _	(please print)
	(piease print)



EXHIBIT A-1 SCOPE OF WORK

I. Purpose of Agreement

The purpose of this contract is to establish an agreement and Scope of Services between the Denver Department of Public Health and Environment (the "Program") and Denver Health and Hospital Authority – Opioid Stewardship Clinical Pharmacist (the "Provider").

The Provider shall provide the identified services for the City under the support and guidance of the Denver Department of Public Health and Environment using best practices and other methods for fostering a sense of collaboration and communication.

II. Program Services and Descriptions

The Provider will be granted funds to provide the following services in the city and county of Denver:

Opioid stewardship is an emerging specialty and an opportunity for Denver Health. Modeled after antimicrobial stewardship programs, the opioid stewardship program will ensure pain management is an organization priority with goals of combatting the opioid epidemic and ensuring regulatory compliance. Integrated into a multidisciplinary team, the opioid stewardship clinical pharmacist specialist (CPS) is uniquely positioned to have significant impacts on patient care and recommended therapy practices. The CPS will support opioid stewardship efforts by providing current, evidence-based education to the healthcare team and patients in addition to creating pain management plans, coordinating care, and managing opioid related adverse drug events.

The following partners will be subcontracted:

N/A

III. Evaluation Plan

The Provider will be evaluated on their fulfillment of the objectives listed below. The Program will provide technical assistance to the Provider to finalize a formal evaluation plan within the first quarter of the project period.

IV. Workplan

Exhibit A Page 1 of 12



SCOPE OF WORK

PROJECT PERIOD: 1/1/2024 - 12/31/2024

	ACTIVITY/MILESTONE	TIMELINE FOR	MEASURABLE
	DESCRIPTION	COMPLETION	OUTCOMES/DELIVERABLES
INSTRUCTIONS	These are the specific	This is the 2024 quarter in which	This is how you will determine that this
	activities/milestones you will	you expect to complete each	activity/milestone has been achieved. This
	complete to work toward your	activity. Indicate "On-going" if the	can be an outcome that your program can
	objectives. Each objective must have a		measure or a deliverable (materials,
	minimum of one activity. You may add		trainings, dashboards, policies, etc.).
	or remove activity/milestone rows to	without an end date. Quarterly reports will request the % of	Quarterly reports will request the submission of deliverables.
	this spreadsheet, as needed.	completion for each activity.	Submission of deliverables.
	Third should be supplied at the state of the	Third about the acception 14th at	This is a base to be a superior of the same of
	Think about the question: What steps do we need to take to achieve our	Think about the question: What is a realistic timeline for us to	Think about the question: How can we
	objectives?	complete this activity?	show that we completed this activity?
		AMPLE OBJECTIVE	
	Ensure the program is acce	ssible to both Spanish and English speakers	5.
EXAMPLE ACTIVITY/MILESTONE 1		Q1	Start of year survey results
EXAMPLE ACTIVITY/MILESTONE 2	to assess language accessibility of the program. Translate 5 primary program documents into	Q2	Five translated documents
,	Spanish.		
EXAMPLE ACTIVITY/MILESTONE 3	Post translated documents on program website.	Q3	Translated documents are available on the program website.
EXAMPLE ACTIVITY/MILESTONE 4	Send monthly program newsletter in both	On-going	12 monthly newsletters in 2024 distributed in Spanish
EXAMPLE ACTIVITY/MILESTONE 5	Spanish and English. Conduct end of year survey with all participants	Q4	and English. End of year survey results
·	to assess language accessibility of the program.		,
The second state of the second state of the	tool above a state of a trace of the same	OBJECTIVE 1	Called the fall and the sub-
developed one order set	ical pharmacist specialist will enhance th	ie Provider's EHR by completing the	following (at a minimum):
2. revised three order sets			
	e best practice advisory (BPA) alert		
•		T _a .	T
ACTIVITY/MILESTONE 1	Recruitment and onboarding of opioid	Q1	Addition of opioid stewardship clinical
	stewardship clinical pharmacist specialist		pharmacist specialist role (1.0 FTE)
ACTIVITY/MILESTONE 2	Begin education efforts for health care	On-going	Incorporation of opioid stewardship into the
•	professionals and patients		pharmacy department. Ongoing education
			with learners and teams as needs /
			opportunities arise.
ACTIVITY/MILESTONE 3	Assess baseline EHR support for	Q2	Identify dashboard builder
	opioid stewardship efforts		
ACTIVITY/MILESTONE 4	Prioritize EHR opportunities	Q3	Identify 1-3 priority opportunities
ACTIVITY/MILESTONE 5	Identify physician(s) / provider (s)	Q3	Identify inidividual(s) with strong interest in
	champion (s)		opioid stewardship
ACTIVITY/MILESTONE 6	Identify ideal rounding team and goal start date	Q4	Rounding team standard work
ACTIVITY/MILESTONE 7	Complete one EHR optimization	Q4	EHR optimization completion
7.011111171111220101127	complete one zim optimization	OBJECTIVE 2	Zim optimization completion
The opioid stewardship clin	ical pharmacist specialist will obtain the		orphine equivalence (MME) usage, compared
	idelines, and develop a recommended g		
ACTIVITY/MILESTONE 1	Recruitment and onboarding of opioid	Q1	Addition of opioid stewardship clinical
	stewardship clinical pharmacist		pharmacist specialist role (1.0 FTE)
ACTIVITY/MILESTONE 2	Begin education efforts for health care	On-going	Incorporation of opioid stewardship into the
	professionals and patients		pharmacy department. Ongoing education
			with learners and teams as needs /
A CTIVITY / A ALL SCT CASE S	Letters de alexane e Control		opportunities arise.
ACTIVITY/MILESTONE 3	Initiate development of metric dashboard	Q3	Gap analysis of recommended metrics for opioid stewardship programs
ACTIVITY/MILESTONE 4	Identify key data needs	Q3	Gap analysis of existing Denver Health
	lacitary key data needs		metrics and meaningful metrics
ACTIVITY/MILESTONE 5	Finalize dashboard development	Q4	Built and validated opioid stewardship
			dashboard
ACTIVITY/MILESTONE 6	Identify key MME usage data	Q4	Opioid stewardship dashboard with at least
			quarterly monitoring and multidisciplinary
		I	review

Exhibit A Page 2 of 12





OBJECTIVE 3		

The opioid stewardship clinical pharmacist specialist will have decreased discharge opioid prescriptions by 5% for patients that have not received opioids in the previous 24 hours.

ACTIVITY/MILESTONE 1	Recruitment and onboarding of opioid	Q1	Addition of opioid stewardship clinical
	stewardship clinical pharmacist		pharmacist specialist role (1.0 FTE)
ACTIVITY/MILESTONE 2	Begin education efforts for health care	On-going	Incorporation of opioid stewardship into the
	professionals and patients		pharmacy department. Ongoing education
ACTIVITY/MILESTONE 3	Explore existing data on opioid	Q3	Discharge prescribing dashboard build and
	discharge prescriptions		validation
ACTIVITY/MILESTONE 4	Identify key prescribing groups with	Q4	Multidisciplinary review of meaningful
	the most impact for change		dashboard metric(s). Identify one quality
			improvement project from dashboard data.

OBJECTIVE 4

OBJECTIVE 4					
The opioid stewardship clin	The opioid stewardship clinical pharmacist specialist will be the pharmacy naloxone coordinator and facilitate at least one program to enhance				
ACTIVITY/MILESTONE 1	Recruitment and onboarding of opioid	Q1	Addition of opioid stewardship clinical		
	stewardship clinical pharmacist		pharmacist specialist role (1.0 FTE)		
	specialist				
ACTIVITY/MILESTONE 2	Begin education efforts for health care	On-going	Incorporation of opioid stewardship into the		
	professionals and patients		pharmacy department. Ongoing education		
			with learners and teams as needs /		
			opportunities arise.		
ACTIVITY/MILESTONE 3	Assess current naloxone programs	Q2	Meet and greet with existing naloxone		
	and resources available to insitution		coordinator		
ACTIVITY/MILESTONE 4	Begin assisting with naloxone efforts	On-going	Process map for existing avenues for		
			naloxone distribution		
ACTIVITY/MILESTONE 5	Identify key metrics for tracking	Q3	Gap analysis of recommended metrics and		
	naloxone efforts		existing metrics at Denver Health		
ACTIVITY/MILESTONE 6	Coordinate institutional naloxone	On-going	Identify and outline role of opioid		
	efforts		stewardship clinical pharmacist specialist in		
			this space in collaboration with existing		
			coordinator		

OBJECTIVE 5

The opioid stewardship clinical pharmacist specialist will have developed a documentation process for provider prescription monitoring to ensure regulatory compliance in collaboration with organization quality efforts.

Complete in comparation in an organization quality en organization				
ACTIVITY/MILESTONE 1	Recruitment and onboarding of opioid	Q1	Addition of opioid stewardship clinical	
	stewardship clinical pharmacist		pharmacist specialist role (1.0 FTE)	
	specialist			
ACTIVITY/MILESTONE 2	Begin education efforts for health care	On-going	Incorporation of opioid stewardship into the	
	professionals and patients		pharmacy department. Ongoing education	
			with learners and teams as needs /	
			opportunities arise.	
ACTIVITY/MILESTONE 3	Multidisciplinary provider prescribing	Q3	Identify key stakeholders for continuous	
	monitoring team		monitoring	
ACTIVITY/MILESTONE 4	Begin meeting routintely with key	Q4	Gap analysis of current regulatory	
	stakeholders and identify current		documentation efforts	
	regulatory documentation efforts			

Exhibit A Page 3 of 12



SCOPE OF WORK

PROJECT PERIOD:

1/1/2025 - 12/31/2025

	ACTIVITY/MILESTONE DESCRIPTION	TIMELINE FOR COMPLETION	MEASURABLE OUTCOMES/DELIVERABLES	
NSTRUCTIONS	objectives. Each objective must have a minimum of one activity. You may add or remove activity/milestone rows to this spreadsheet, as needed. Think about the question: What steps	will be conducted throughout the entire year without an end date. Quarterly reports will request the % of completion for each activity. Think about the question: What	This is how you will determine that this activity/milestone has been achieved. This can be an outcome that your program can measure or a deliverable (materials, trainings, dashboards, policies, etc.). Quarterly reports will request the submission of deliverables. Think about the question: How can we show that we completed this activity?	
	EX	AMPLE OBJECTIVE		
	Ensure the program is acces	sible to both Spanish and English speakers	i.	
EXAMPLE ACTIVITY/MILESTONE 1	Conduct start of year survey with all participants to assess language accessibility of the program.	2025 Q1	Start of year survey results	
EXAMPLE ACTIVITY/MILESTONE 2	Translate 5 primary program documents into Spanish.	2025 Q2	Five translated documents	
EXAMPLE ACTIVITY/MILESTONE 3	Post translated documents on program website.	2025 Q3	Translated documents are available on the program website.	
EXAMPLE ACTIVITY/MILESTONE 4	Send monthly program newsletter in both Spanish and English.	On-going	12 monthly newsletters in 2024 distributed in Spanish and English.	
EXAMPLE ACTIVITY/MILESTONE 5	Conduct end of year survey with all participants to assess language accessibility of the program.	2025 Q4	End of year survey results	

OBJECTIVE 1

The opioid stewardship clinical pharmacist specialist will enhance the Provider's EHR by completing the following (at a minimum):

- 1. developed one order set
- 2. revised three order sets
- 3. developed or revised one best practice advisory (BPA) alert

ACTIVITY/MILESTONE 1	Continue educations efforts	On-going	Ongoing education with learners and teams
			as needs / opportunities arise.
ACTIVITY/MILESTONE 2	Round with appropriate	On-going	Rounding standard work
	multidisciplinary team		
ACTIVITY/MILESTONE 3	Provide consultations ad hoc to other	On-going	i-Vent tracking
	providers as needed		
ACTIVITY/MILESTONE 4	Provider treatment plan	On-going	i-Vent tracking
	recommendations		
ACTIVITY/MILESTONE 5	Support any ToC needs	On-going	Drug information question tracker vs i-Vent
			tracking
ACTIVITY/MILESTONE 6	Complete one EHR optimization	2025 Q1	EHR Optimization Ticket #
ACTIVITY/MILESTONE 7	Complete one EHR optimization	2025 Q3	EHR Optimization Ticket #
		ODJECTIVE 3	

OBJECTIVE 2

The opioid stewardship clinical pharmacist specialist will obtain the baseline daily inpatient milligram morphine equivalence (MME) usage, compared to national best-practice guidelines, and develop a recommended goal decrease (as appropriate).

ACTIVITY/MILESTONE 1	Continue educations efforts		Ongoing education with learners and teams as needs / opportunities arise.
ACTIVITY/MILESTONE 2	Maintain dashboard metrics	On-going	Dashboard surveillance standard work
ACTIVITY/MILESTONE 3	Compare institutional MME usage to	On-going	Define internal metric and benchmark
	best practice - 2024 Q4		
ACTIVITY/MILESTONE 4	Recommend goal MME usage	2025 Q2	Evidence of quality improvement project
	decrease (as appropriate)		progress/completion

Exhibit A Page 4 of 12





$\overline{}$	-	 _	гιν	-	-

The opioid stewardship clinical pharmacist specialist will have decreased discharge opioid prescriptions by 5% for patients that have not received opioids in the previous 24 hours.

ACTIVITY/MILESTONE 1	Continue educations efforts	On-going	Ongoing education with learners and teams
			as needs / opportunities arise.
ACTIVITY/MILESTONE 2	Engage key prescribing group to identify opportunity for prescription decrease		Evidence of quality improvement project progress
ACTIVITY/MILESTONE 3	Implement opportunity initiative	·	Evidence of quality improvement project completion

The opioid stewardship clinical pharmacist specialist will be the pharmacy naloxone coordinator and facilitate at least one program to enhance distribution of naloxone to Denver Health patients and the community.

	· · · · · · · · · · · · · · · · · · ·	-1	
ACTIVITY/MILESTONE 1	Continue educations efforts	On-going	Ongoing education with learners and teams
			as needs / opportunities arise.
ACTIVITY/MILESTONE 2	Coordinate institutional naloxone	On-going	Identify and outline role of opioid
	efforts		stewardship clinical pharmacist specialist in
			this space in collaboration with existing
			coordinator
ACTIVITY/MILESTONE 3	Identify one additional naloxone	2025 Q2	Identify and outline role of opioid
	program initiative		stewardship clinical pharmacist specialist in
			this space in collaboration with existing
			coordinator
ACTIVITY/MILESTONE 4	Begin additional naloxone program	2025 Q3	Identify and outline role of opioid
			stewardship clinical pharmacist specialist in
			this space in collaboration with existing
			coordinator
ACTIVITY/MILESTONE 5	Sustain additional naloxone program	On-going	Identify and outline role of opioid
			stewardship clinical pharmacist specialist in
			this space in collaboration with existing
			coordinator
		OBJECTIVE 5	

The opioid stewardship clinical pharmacist specialist will have developed a documentation process for provider prescription monitoring to ensure regulatory compliance in collaboration with organization quality efforts.

ACTIVITY/MILESTONE 1	Continue educations efforts		Ongoing education with learners and teams
ACTIVITY/MILESTONE 2	Develop documentation process in	2025 Q1	Provider prescription monitoring standard
ACTIVITY/MILESTONE 3	Refine documentation efforts with key	2025 Q1	Multidisciplinary review of standard work
ACTIVITY/MILESTONE 4	Implement documentation process	2025 Q2	Evidence of provider-to-provider feedback process
ACTIVITY/MILESTONE 5	Sustain/support documentation process		Evidence of provider-to-provider feedback process

Page 5 of 12 Exhibit A



SCOPE OF WORK

PROJECT PERIOD: 1/1/2026 - 12/31/2026

	ACTIVITY/MILESTONE DESCRIPTION	TIMELINE FOR COMPLETION	MEASURABLE OUTCOMES/DELIVERABLES
INSTRUCTIONS	These are the specific activities/milestones you will complete to work toward your objectives. Each objective must have a minimum of one activity. You may add or remove activity/milestone rows to this spreadsheet, as needed. Think about the question: What steps do we need to take to achieve our objectives?	will be conducted throughout the entire year without an end date. Quarterly reports will request the % of completion for each activity. Think about the question: What	trainings, dashboards, policies, etc.). Quarterly reports will request the
		AMPLE OBJECTIVE	
	Ensure the program is acces	ssible to both Spanish and English speakers	5.
EXAMPLE ACTIVITY/MILESTONE 1	Conduct start of year survey with all participants to assess language accessibility of the program.	2026 Q1	Start of year survey results
EXAMPLE ACTIVITY/MILESTONE 2	Translate 5 primary program documents into Spanish.	2026 Q2	Five translated documents
EXAMPLE ACTIVITY/MILESTONE 3	Post translated documents on program website.	2026 Q3	Translated documents are available on the program website.
EXAMPLE ACTIVITY/MILESTONE 4	Send monthly program newsletter in both Spanish and English.	On-going	12 monthly newsletters in 2024 distributed in Spanish and English.
EXAMPLE ACTIVITY/MILESTONE 5	Conduct end of year survey with all participants to assess language accessibility of the program.	2026 Q4	End of year survey results

OBJECTIVE :

The opioid stewardship clinical pharmacist specialist will enhance the Provider's EHR by completing the following (at a minimum):

- 1. developed one order set
- 2. revised three order sets
- 3. developed or revised one best practice advisory (BPA) alert

ACTIVITY/MILESTONE 1	Continue educations efforts	On-going	Ongoing education with learners and teams
			as needs / opportunities arise.
ACTIVITY/MILESTONE 2	Round with appropriate	On-going	Rounding standard work
	multidisciplinary team		
ACTIVITY/MILESTONE 3	Provide consultations ad hoc to other	On-going	i-Vent tracking
	providers as needed		
ACTIVITY/MILESTONE 4	Provider treatment plan	On-going	i-Vent tracking
	recommendations		
ACTIVITY/MILESTONE 5	Support any ToC needs	On-going	Drug information question tracker vs i-Vent
			tracking
ACTIVITY/MILESTONE 6	Complete one EHR optimization	2026 Q1	EHR Optimization Ticket #
ACTIVITY/MILESTONE 7	Best practice sharing through CAM	On-going	Best practice education collaborative efforts
	academy		with CAM
ACTIVITY/MILESTONE 8	Complete one EHR optimization	2026 Q3	EHR Optimization Ticket #

OBJECTIVE 2

The opioid stewardship clinical pharmacist specialist will obtain the baseline daily inpatient milligram morphine equivalence (MME) usage, compared to national best-practice guidelines, and develop a recommended goal decrease (as appropriate).

ACTIVITY/MILESTONE 1	Continue educations efforts	On-going	Ongoing education with learners and teams
			as needs / opportunities arise.
ACTIVITY/MILESTONE 2	Maintain dashboard metrics	On-going	Dashboard surveillance standard work
ACTIVITY/MILESTONE 3	Develop project plan for daily MME	2026 Q1	Evidence of quality improvement project
	usage decrease (as appropriate) - 2025		completion
	Q4		
ACTIVITY/MILESTONE 4	Best practice sharing through the CAM	On-going	Best practice education collaborative efforts
	Academy - 2026 Q1-3		with CAM

Exhibit A Page 6 of 12





OBJECTIVE 3

The opioid stewardship clinical pharmacist specialist will have decreased discharge opioid prescriptions by 5% for patients that have not received opioids in the previous 24 hours.

ACTIVITY/MILESTONE 1	Continue educations efforts	On-going	Ongoing education with learners and teams
			as needs / opportunities arise.
ACTIVITY/MILESTONE 2	Engage key prescribing group to	2026 Q1	Evidence of quality improvement project
	identify opportunity for prescription		draft
	decrease - 2025 Q1		
ACTIVITY/MILESTONE 3	Best practice sharing through the CAM	On-going	Best practice education collaborative efforts
	Academy - 2026 Q1-3		with CAM
ACTIVITY/MILESTONE 4	Implement opportunity initiative	2026 Q3	Evidence of quality improvement project
			implementation
ACTIVITY/MILESTONE 5	Maintain prescription reduction 2026	On-going	Evidence of quality improvement project
	Q2-3		surveillance

OBJECTIVE 4

The opioid stewardship clinical pharmacist specialist will be the pharmacy naloxone coordinator and facilitate at least one program to enhance distribution of naloxone to Denver Health patients and the community.

ACTIVITY/MILESTONE 1	Continue educations efforts	On-going	Ongoing education with learners and teams		
			as needs / opportunities arise.		
ACTIVITY/MILESTONE 2	Coordinate institutional naloxone	On-going	Identify and outline role of opioid		
	efforts		stewardship clinical pharmacist specialist in		
			this space in collaboration with existing		
			coordinator		
ACTIVITY/MILESTONE 3	Sustain additional naloxone	On-going	Identify and outline role of opioid		
	program(s) as applicable		stewardship clinical pharmacist specialist in		
			this space in collaboration with existing		
			coordinator		
ACTIVITY/MILESTONE 4	Explore harm-reduction program as	On-going	Assessment of current harm-reduction		
	applicable		efforts and program proposal as applicable		
ACTIVITY/MILESTONE 5	Best practice sharing through the CAM	On-going	Best practice education collaborative efforts		
	Academy - 2026 Q1-3		with CAM		
ODIFICATIVE E					

OBJECTIVE 5

The opioid stewardship clinical pharmacist specialist will have developed a documentation process for provider prescription monitoring to ensure regulatory compliance in collaboration with organization quality efforts.

ACTIVITY/MILESTONE 1	Continue educations efforts	On-going	Ongoing education with learners and team	
			as needs / opportunities arise.	
ACTIVITY/MILESTONE 2	Sustain/support documentation	On-going	i-Vent tracking & report out to Acute Care	
	process		Clinical Team Meeting	
ACTIVITY/MILESTONE 3	Best practice sharing through the CAM	On-going	Best practice education collaborative efforts	
	Academy - 2026 Q1-3		with CAM	

V. Performance Management and Reporting

The Provider is required to report on activities, program outputs, and outcomes as outlined in this section and work in partnership with the Program staff for shared learning to aid Denver's ongoing opioid abatement efforts. Monitoring will be performed by Denver Department of Public Health and Environment (DDPHE) staff and/or designee. The Provider should expect to share all data and evaluation products with DDPHE.

Performance management and reporting may include:

Exhibit A Page 7 of 12





- 1. Program Monitoring/Evaluation-Related Activities: Review and analysis of current program information to determine the extent to which the Provider is achieving agreed upon goals. This may include the review and analysis of evaluation dashboards, primary provider data, provider aggregate reports, client and partner feedback, the Provider's evaluation plan referenced in Section III, reporting forms, and annual reports. As needed, the Program may attend evaluation site visits or check-ins to understand progress towards agreed-upon goals in this agreement.
- 2. **Fiscal Monitoring:** Review financial systems and billings to ensure that contract funds are allocated and expended in accordance with the terms of the agreement.
- 3. **Administrative Monitoring:** Monitoring to ensure that the requirements of the contract document, Federal, State and City and County regulations, and DDPHE policies are being met.

The table below summarizes required reporting activities and due dates. The Program may require additional measures to be reported or change the frequency of reporting throughout the period of performance given the evolving nature of the drug overdose epidemic.

Activity	Description	Due Date	Submit
			to
Report 1	Performance Measure and Data Monitoring	Monthly	OAF
			Program
Evaluation Plan	The Provider will submit a plan outlining how	End of	OAF
	they will measure fulfillment of objectives	Q1	Program
	within the first quarter of the project period		
Report 2	Evaluation Monitoring	Quarterly	OAF
			Program
Report 3	Final Report	Annually	OAF
			Program
Annual Site Visit	Onsite evaluation of project outcomes and	Annually	OAF
	fiscal monitoring		Program
Other reports and	To be determined (TBD)	TBD	TBD
data sharing as			
requested			
Program Meetings	Attendance and participation at regularly	Monthly	N/A
	scheduled community of practice meetings,		
	grantee check-ins, office hours, and		
	collaborative partner meetings		

VI. Budget

Exhibit A Page 8 of 12





The budget for this agreement is outlined below.

Term	1/1/2025 - 12/31/2025	1			
	Budget Cate	gories	<u>.</u>		
	Personnel and Adminis		es		
Salary Employees					
Position Title Program Manager/Evaluator Clinical Pharmacist	Description of Work The Project Manager/Evaluator will ov The Clinical Pharmacist Specialist will s		Percent of Time 5% 100%	Salary + Fringe Benefits 250,014.00 180,784.00	Total Amount Requested from OD2A Grant \$12,501.00 \$180,784.00
			Total Pers	onnel Services	\$193,285.00
	Other / Miscel	laneous			
ltem	Description	Does this budget item support the Scope of Work?	Quantity	Per Item Cost	Total Amount Requested from OD2A Grant
			,		
Conference 1	ASAM 4/24/-4/27		1	1415	\$1,415.00
Conference 2	Mayo Opioid 09/11 -9/13		1	895	\$895.00
Air	Mayo Registration to Nashville		1	700	\$700.00
M&IE	M&IE to Mayo Conference		1	301	\$301.00
Transportation	To hotel, airport, and conference.		1	500	\$500.00
Naloxone Lodging	Supplies-Pharmacy/Drugs Naloxone Mayo Registration to Nashville		1 4	85,376.76 248	\$85,376.76 \$992.00
				Total Other	
	TOTAL DIRECT COSTS (perating, Pers	onnel, Other)	\$283,464.76
Indirect Item Description			Total Amount Requested from OD2A Grant		
Indirect Costs: DDPHE policy places a ten percent (10%) cap on reimbursement for indirect rate (if applicable): Indirect Costs: DDPHE policy places a ten percent (10%) cap on reimbursement for indirect costs, based on the total contract budget.				\$28,346.00	
				IRECT COSTS	
	TOTAL A	MOUNT RE	QUESTED	FROM OAF	\$311,810.76

Exhibit A Page 9 of 12



SCOPE OF WORK

Term	1/1/2026 - 12/31/2026						
Budget Categories							
Personnel and Administrative Services							
Salary Employees	Salary Employees						
		Does this					
		budget item			Total Amount		
		support the		Salary +	Requested		
		Scope of	Percent of	Fringe	from OD2A		
Position Title	Description of Work	Work?	Time	Benefits	Grant		
Program Manager/Evaluator	The Project Manager/Evalua	yes	5%	269,593.00	\$13,480.00		
Clinical Pharmacist	The Clinical Pharmacist Speci	yes	100%	194,940.00	\$194,940.00		
			Total Pers	onnel Services	\$208,420.00		
	TOTAL DIRECT COSTS (Supplies & O	perating, Pers	onnel, Other)	\$208,420.00		
	Ind	irect					
					Total Amount		
					Requested		
		Description			from OD2A		
Item		Grant					
	Indirect Costs: DDPHE policy places a ten percent (10%) cap on						
Indirect rate (if applicable): reimbursement for indirect costs, based on the total contract budget.					\$20,842.00		
				IRECT COSTS			
TOTAL AMOUNT REQUESTED FROM OAF					\$229,262.00		

Total Contract term: 1/1/2024-12/31/2026

Maximum Contract Amount including any indirect costs: \$743,478.75. \$99,196.76 of unspent Y1 funding has been rolled over into the Y2 budget.

Indirect Cost Limit: The Provider's total indirect costs cannot exceed 10% of the Maximum Grant Amount as listed in the Budget. Indirect costs are defined as the administrative costs that are incurred for common or joint activities that cannot be identified specifically with a particular project or program. Administrative costs can be included in indirect costs and defined as the costs incurred for usual and recognized overhead, including management and oversight of specific programs funded under this contract; and other types of program support such as quality assurance, quality control, and related activities. Direct costs are costs that can be directly charged to the Program, and which are incurred in the provision of direct services.

Examples of indirect costs include: Salaries and related fringe benefits for accounting, secretarial, and management staff, including those individuals who produce, review and sign monthly program and fiscal reports; Consultants who perform administrative, nonservice delivery functions; General office supplies; Travel costs for administrative and management staff; General office printing and photocopying; General liability insurance; Audit fees, rent, utilities, general office supplies and equipment/technology

VII. Invoice

Exhibit A Page 10 of 12



EXHIBIT A-1 SCOPE OF WORK

This is a sample invoice. This template is subject to change.

VIII. Payments

Invoices, spending reports, and backup documentation, if required, shall be completed and emailed to OAFInvoices@denvergov.org no later than 45 days after month end, including final invoice.

All non-personnel purchases of \$1,000 or more must have back up documentation submitted with the invoice and report each month to DDPHE. The Provider is required to keep on file all documentation of purchase of items and/or payment less than \$1,000 but does not need to submit those back up documents with invoice and report unless the Program specifically requests it.

The Provider shall use the DDPHE invoice template in Section VII unless the Program gives approval for the Provider to use their own template. In the event of extenuating circumstances, invoices can be processed with immediate payment terms.

IX. General Requirements

This award is funded through DDPHE's Opioid Abatement Funds (OAF) Program. The City and County of Denver, along with other local governments throughout Colorado and the United States, filed a lawsuit against opioid manufacturers, distributors and pharmacies seeking to hold them responsible for their contributions to the opioid epidemic. Those lawsuits resulted in certain litigation settlements and the availability of funds to address and abate the impacts of opioid misuse. DDPHE created the OAF Program to support the Denver Opioid Abatement Council (DOAC) in overseeing the equitable and effective disbursement of settlement funds throughout the city and county of Denver. The DOAC and other regional opioid abatement councils in Colorado are working in partnership with the Colorado Office of the Attorney General to ensure settlement funds are utilized in accordance with the terms of the Colorado Opioids Settlement Memorandum of Understanding (MOU). Awardees must also comply with the terms of the MOU.

Contract amendments to include additional years of service will be dependent on funds received, program strategy and goals, and approval by the DOAC. The Program may require the Provider to submit updated budgets and scopes of work to be considered for continued funding.

The Provider shall follow the OAF Program Communication Guidelines, including displaying signage and/or online banners noting that the program receives funding from DDPHE and the OAF Program. The OAF Program will provide electronic files (e.g., logos) and guidelines for printing and/or displaying on websites, social media accounts, and other materials.

Exhibit A Page 11 of 12



EXHIBIT A-1 SCOPE OF WORK

X. Other

Additional document and activity requirements that may be requested for this contract:

- Organizational Chart, Financial Reports, etc.
- Updated Certificate of Insurance
- Presenting progress and outcomes to the Denver Opioid Abatement Council
- Collaborating with the OAF Program on data analysis and needs assessments
- Reports and information for Program Evaluation, as required
- The Provider shall submit updated documents which are directly related to the delivery of services

Exhibit A Page 12 of 12